<?xml version="1.0" encoding="UTF-8"?>
<ref id="B22-viruses-12-00518">
 <label>22.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Woo</surname>
    <given-names>E.J.</given-names>
   </name>
   <name>
    <surname>Moro</surname>
    <given-names>P.L.</given-names>
   </name>
   <name>
    <surname>Cano</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Jankosky</surname>
    <given-names>C.</given-names>
   </name>
  </person-group>
  <article-title>Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System</article-title>
  <source>Vaccine</source>
  <year>2017</year>
  <volume>35</volume>
  <fpage>5618</fpage>
  <lpage>5621</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.08.047</pub-id>
  <pub-id pub-id-type="pmid">28886946</pub-id>
 </element-citation>
</ref>
